Nephrology

Bariatric surgery, particularly sleeve gastrectomy, may improve survival and kidney transplant access in older adults with obesity and ESKD.

A curated recap of 8 impactful trial updates from the American Society of Nephrology Kidney Week 2025.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and new Crohn's disease guidelines, in this week's essential news roundup.

Phase 3 trial shows MIL62 accelerates remission, reduces relapse risk, and improves kidney function compared with cyclosporine A in adults with primary MN.

Non-RASi antihypertensive use before pregnancy in women with IgAN increased the risk of severe HDP and preterm delivery.

Dual BLyS/APRIL inhibition with telitacicept cut proteinuria and maintained kidney function in adults with IgA nephropathy.

ASN insights on felzartamab, a CD38-targeted therapy, show sustained immune modulation in IgA nephropathy, offering a novel treatment approach.

Dual BLyS/APRIL inhibition with telitacicept led to significant 24h-UPCR reductions, lower progression-risk thresholds, and stable eGFR compared with placebo.

ASN 2025 VALIANT data on pegcetacoplan show proteinuria reduction, including remission or reduction, in adolescents with C3G and IC-MPGN.

Tumlin discussed improvements in UPCR and Gd-IgA1 seen with povetacicept.

Discover groundbreaking insights from ASN Kidney Week on the SURPASS-CVOT trial.

Weir pointed out that significant benefits were seen with concurrent SGLT2 inhibitor use.

McGill emphasizes new exciting data shared at ACR 2025.

Acute kidney injury mortality rises in wealthier nations, highlighting urgent need for targeted prevention strategies.

Sibeprenlimab shows promising results in reducing proteinuria and improving kidney health in IgA nephropathy.

A recent study reveals that younger patients with glomerular disease face a higher lifetime risk of kidney failure despite similar progression rates.

Neuen and Gale break down groundbreaking insights on Alport syndrome and glomerular diseases, including RaDaR registry data.

Discover groundbreaking findings from the FINE-ONE trial on finerenone, offering hope for type 1 diabetes patients with CKD.

Sparsentan shows superior proteinuria reduction in pediatric FSGS patients, setting the stage for potential FDA approval.

Discover groundbreaking insights on SGLT2 inhibitors and their impact on kidney health, cardiovascular outcomes, and patient care at ASN Kidney Week.

New research shows nearly all adults with hypertensive chronic kidney disease benefit from a <120 mm Hg target.

SGLT2 inhibitors show significant kidney protection for chronic kidney disease regardless of diabetes status or albumin levels.

New data on daily fish oil supplementation prompts discussions on clinical recommendations.

Cheung explores the effect of sparsentan on urinary biomarkers in treatment-naive patients with IgA nephropathy.